Tech Center 1600 • Art Units: 1621 1622 1626 1647
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18289214 | COMPOUNDS FOR MODULATING PLATELET-TYPE 12-(S)-LIPOXYGENASE AND METHODS OF USE FOR SAME | Non-Final OA | The Regents of The University of California |
| 18272673 | SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES | Non-Final OA | BASF SE |
| 18779430 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18039774 | METHOD FOR PREPARING DEUTERATED ANTHRACENE COMPOUND, REACTION COMPOSITION, DEUTERATED ANTHRACENE COMPOUND AND COMPOSITION | Non-Final OA | LG CHEM, LTD. |
| 17637565 | COMPOSITION FOR PREVENTING OR TREATING BACTERIAL INFECTIOUS DISEASE COMPRISING 4-GINGEROL DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18399092 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 17419965 | SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 17912485 | SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 | Non-Final OA | The Board of Regents of The University of Texas System |
| 17441149 | INHIBITION OF NAMPT AND/OR SARM1 FOR THE TREATMENT OF AXONAL DEGRADATION | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 17761830 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18254094 | METHOD OF PREPARING HETEROGENEOUS LINEAR CARBONATE ADOPTING CATALYTIC FILTERING | Non-Final OA | LOTTE CHEMICAL CORPORATION |
| 16980401 | COMPOUNDS AND USES FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS ASSOCIATE WITH OR AGGREVATED BY IMPARED MITOPHAGY | Non-Final OA | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
| 17928468 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 18296538 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | Non-Final OA | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. |
| 18581289 | PRECURSOR COMPOUNDS FOR PROVIDING RETINOIDS OF THE VATAMIN A5 PATHWAY AND USES THEREOF | Non-Final OA | UNIVERSITÉ DE STRASBOURG |
| 18561962 | CRYSTALLINE FORM OF TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Non-Final OA | ONCONIC THERAPEUTICS INC. |
| 17766889 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | Final Rejection | D. E. Shaw Research, LLC |
| 18234826 | 2-S RIMANTADINE AND 2-R RIMANTADINE FOR TREATING CANCER | Non-Final OA | Toragen, Inc. |
| 18134751 | In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof | Non-Final OA | Kaunas University of Technology |
| 18352959 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Ultragenyx Pharmaceutical Inc. |
| 18117295 | TABLET DOSAGE FORMS FOR LIPID-BASED DRUG DELIVERY SYSTEMS | Non-Final OA | ABITEC Corporation |
| 18024010 | USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES | Non-Final OA | Min CHEN |
| 17430781 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR | Non-Final OA | ZEPHAPHARM LTD |
| 17909589 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | Non-Final OA | OM PHARMA SA |
| 17754924 | MACROCYCLIC AND CAGE-LIKE MOLECULE BASED ON BIPHEN[n]ARENE AND DERIVATIVE, SYNTHESIS METHOD AND USE THEREOF | Final Rejection | TIANJIN NORMAL UNIVERSITY |
| 17675507 | MONOUNSATURATED FATTY ACID COMPOSITION AND USE FOR TREATING FATTY LIVER DISEASE | Non-Final OA | Burke & Boyer, Inc. |
| 17439151 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF PAIN | Non-Final OA | NEUROCYCLE THERAPEUTIC, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy